Integrating Public Health Concerns into Patent Legislation in Developing Countries
(2000; 140 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoTHE SOUTH CENTRE
Ver el documentoFOREWORD
Ver el documentoACKNOWLEDGEMENTS
Ver el documentoGLOSSARY*
Abrir esta carpeta y ver su contenidoI. INTRODUCTION
Abrir esta carpeta y ver su contenidoII. PATENTABLE SUBJECT MATTER
Abrir esta carpeta y ver su contenidoIII. SCOPE OF CLAIMS
Abrir esta carpeta y ver su contenidoIV. PATENTABILITY REQUIREMENTS
Abrir esta carpeta y ver su contenidoV. SPECIAL CASES IN PHARMACEUTICALS
Abrir esta carpeta y ver su contenidoVI. DISCLOSURE
Cerrar esta carpetaVII. EXCEPTIONS TO EXCLUSIVE RIGHTS
Abrir esta carpeta y ver su contenidoVII.1 Experimental Use
Cerrar esta carpetaVII.2 Early Working
Ver el documentoVII.2.1 Options - Early Working
Abrir esta carpeta y ver su contenidoVII.3 Parallel Imports
Abrir esta carpeta y ver su contenidoVII.4 Individual Prescriptions
Abrir esta carpeta y ver su contenidoVIII. EXAMINATION AND OBSERVATION PROCEDURES
Abrir esta carpeta y ver su contenidoIX. CLAIMS INTERPRETATION
Abrir esta carpeta y ver su contenidoX. COMPULSORY LICENSING
Ver el documentoXI. FINAL REMARKS
Ver el documentoREFERENCES
Ver el documentoBACK COVER
 

VII.2.1 Options - Early Working

The “early working” exception, as noted above, may in some cases be considered as part of the experimental use exception. However, given the importance of this issue, and the uncertainty surrounding judicial interpretation, it seems advisable to include a specific provision on the matter. It may include the following:

Early Working
Model Option

The patent shall have no effect with respect to any acts, including testing, using, making or selling the invention, solely for purposes reasonably related to the development and submission of information required under any law of ... (country) or of another country that regulates the manufacture, construction, use or sale of any product.

The proposed wording includes, among the possible non-infringing acts, the limited manufacturing of the patented product in order to undertake the tests required by the health authorities. This option would not allow for production and stockpiling before the expiration of the patent.

Ir a la sección anterior
Ir a la siguiente sección
 
 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019